TCA
ALNY icon

Transcend Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Transcend Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-620
Closed -$247K – 724
2025
Q4 		$247K Sell
620
-279
-31% -$123K 0.02% 592
2025
Q3 		$410K Buy
+899
New +$366K 0.03% 426

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Transcend Capital Advisors's ALNY Position: Q1 2026 in Review

Transcend Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 620 shares — an estimated $247K sold.

Transcend Capital Advisors first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $410K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Transcend Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Transcend Capital Advisors sold 620 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $247K.
  • Transcend Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Transcend Capital Advisors's Alnylam Pharmaceuticals position peaked at $410K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.